Clinical Trial Update: Post-Authorization Long-term Safety Surveillance on Antihypertensive Treatment With Kanarb® (Fimasartan)

View source ↗

Summary

Post-authorization long-term safety surveillance study of Kanarb® (fimasartan) in essential hypertension has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension

Drugs mentioned

• Kanarb (Fimasartan)

Snippet

Sponsor: Boryung Pharmaceutical Co., Ltd | Conditions: Essential Hypertension | Status: COMPLETED | Results posted: 2019-02-01